Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03475186 · ClinicalTrials.gov registry record · Phase 2
Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT03475186 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 75 participants.
The verdict
NCT03475186, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
This study is to determine if an oral drug called Ramipril can lower the chance of memory loss in patients with glioblastoma getting chemoradiation. Patients will take Ramipril during chemoradiation and continue until 4 months post-treatment. Memory loss will be assessed using several neurocognitive tests throughout the duration of the study.
Interventions
- DRUG Ramipril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2019-03-25 |
| Est. Completion | 2025-03-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03475186
The ClinicalTrials.gov registry entry for NCT03475186 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ramipril is the first listed.
NCT03475186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03475186 about?
NCT03475186 is a clinical study titled "Testing Ramipril to Prevent Memory Loss in People With Glioblastoma". This study is to determine if an oral drug called Ramipril can lower the chance of memory loss in patients with glioblastoma getting chemoradiation. Patients will take Ramipril during chemoradiation and continue until 4 months post-treatment. Memory loss will be assessed using several neurocognitive...
What is the current status of trial NCT03475186?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2019-03-25. Estimated completion is 2025-03-25.
What interventions are being tested in trial NCT03475186?
The interventions under investigation include: Ramipril (DRUG).
Who is sponsoring clinical trial NCT03475186?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.